endast för forskning

Favipiravir (T-705) RNA-polymerashämmare

Name: Favipiravir (T-705)
Brand: Selleck Chemicals
SKU: S7975
Rating: 5 (27 reviews)

Kat.nr.: S7975

Favipiravir (T-705) är en potent och selektiv RNA-beroende RNA-polymeras-hämmare som används för att behandla infektioner orsakade av influenza virus.

Favipiravir (T-705) DNA/RNA Synthesis Hämmare Chemical Structure

Kemisk struktur

Molekylvikt: 157.1

Hoppa till

Kvalitetskontroll (Quality Control)

Batch: Renhet: 99.97%

99.97

Relaterade mål	HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF
Övrigt DNA/RNA Synthesis Inhibitorer	CX-5461 (Pidnarulex) SCR7 RK-33 EED226 BMH-21 Carmofur Triapine (3-AP) YK-4-279 Halofuginone Tegafur (FT-207)

Cellodling, behandling & arbetskoncentration
(Cell Culture, Treatment & Working Concentration)

Cellinjer	Analystyp	Koncentration	Inkubationstid	Aktivitetsbeskrivning	PMID
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 0.38 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant , Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 0.19 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis, EC50 = 0.45 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana, EC50 = 0.57 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-， Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet, EC50 = 0.83 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-susceptible ,Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 0.89 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days , EC50 = 0.89 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet , EC50 = 0.96 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af, EC50 = 1.21 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant ,Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 1.21 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.21 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against adamantane，Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after, EC50 = 1.27 μM.	20350949
MDCK	Antiviral assay			Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 1.3 μM.	17194832
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.32 μM.	23419738
MDCK	Antiviral assay			Antiviral activity against adamantane-, Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 1.341 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.4 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.4 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-， Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.46 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.53 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 1.59 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-，Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry, EC50 = 1.59 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 1.72 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.85 μM.	20350949
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.93 μM.	23419738
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.94 μM.	23419738
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant，Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.97 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a, EC50 = 2.23 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 2.48 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 2.55 μM.	20350949
MDCK	Antiviral assay			Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 2.6 μM.	17194832
MDCK	Antiviral assay			Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 2.6 μM.	17194832
MDCK	Antiviral assay		24 hrs	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira, EC50 = 2.7 μM.	27120583
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 2.84 μM.	23419738
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 2.87 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-, Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 2.93 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte, EC50 = 2.93 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u, EC50 = 3 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 3.25 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against adamantane-susceptible , Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a, EC50 = 3.38 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 3.63 μM.	20350949
MDCK	Antiviral assay			Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 3.8 μM.	17194832
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 3.95 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant, Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 4.01 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.08 μM.	20350949
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition, EC50 = 4.14 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.2 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy, EC50 = 4.46 μM.	20350949
MDCK	Antiviral assay			Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 4.5 μM.	17194832
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 4.52 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-susceptible,Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.7 μM.	20350949
MDCK	Antiviral assay		1 hr	Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 4.71 μM.	23419738
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.9 μM.	20350949
Vero	Antiviral assay		7 to 8 days	Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 5 μM.	17606691
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-,Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 5.03 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 5.03 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic, EC50 = 5.22 μM.	20350949
MDCK	Antiviral assay			Antiviral activity agains, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 5.22 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 5.3 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi, EC50 = 5.41 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant, Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole, EC50 = 5.99 μM.	20350949
Vero	Antiviral assay		7 to 8 days	Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM.	17606691
Vero	Antiviral assay		7 to 8 days	Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM.	17606691
MDCK	Antiviral assay			Antiviral activity against, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re, EC50 = 6.62 μM.	20350949
MDCK	Antiviral assay	1 hr	3 days	Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 6.95 μM.	23419738
MDCK	Antiviral assay			Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 7.7 μM.	17194832
MDCK	Antiviral assay		3 days	Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 8.3 μM.	29906392
MDCK	Antiviral assay		3 days	Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 9 μM.	29906392
MDCK	Antiviral assay		3 days	Antiviral activity against adamantane-resistant,Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 10.2 μM.	20350949
MDCK	Antiviral assay			Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 11.5 μM.	17194832
MDCK	Antiviral assay			Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 12.1 μM.	17194832
Vero-A	Antiviral assay			Antiviral activity against Chikungunya virus venturini isolate (Italy 2008) infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 16 μM.	28689975
MDCK	Antiviral assay			Antiviral activity against oseltamivir-susceptible, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli, EC50 = 22.48 μM.	20350949
MDCK	Antiviral assay		3 days	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 24 μM.	29906392
Vero-A	Antiviral assay			Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM.	28689975
Vero-A	Antiviral assay			Antiviral activity against Chikungunya virus LR2006-OPY1 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM.	28689975
MDCK	Antiviral assay		3 days	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 26 μM.	29906392
MDCK	Antiviral assay			Antiviral activity against 0.001 MOI adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at, NULL = NULL μM.	20350949
MDCK	Antiviral assay			Antiviral activity against 0.001 MOI adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture , NULL = NULL μM.	20350949
MDCK	Antiviral assay	128 uM		Antiviral activity against adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM af, NULL = NULL μM.	20350949
MDCK	Antiviral assay	128 uM		Antiviral activity against adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM , NULL = NULL μM.	20350949
Vero	Antiviral assay	6400 uM	up to 12 hrs	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as time required for inhibition of viral replication at 6400 uM up to 12 hrs post-viral infection, NULL = NULL μM.	18955536
MDCK	Antiviral assay		0 to 2 hrs	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 2 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM.	30192544
MDCK	Antiviral assay		5 to 8 hrs	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 5 to 8 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM.	30192544
MDCK	Antiviral assay		0 to 10 hrs	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 10 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM.	30192544
MDCK	Antiviral assay		2 to 5 hrs	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 2 to 5 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM.	30192544
MDCK	Antiviral assay	10 uM	up to 8 hrs	Antiviral activity against Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells assessed as inhibition of early stages of viral replication at 10 uM up to 8 hrs by crystal violet staining based plaque reduction assay dependent time-of, NULL = NULL μM.	30292897
MDCK	Antiviral assay	100 uM	12 hrs	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA synthesis at 100 uM preincubated with cells for 12 hrs followed by viral infection measured after 10 hrs post infection by RT-qPCR metho, NULL = NULL μM.	29906392
MDCK	Antiviral assay	250 uM	10 hrs	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA sytheis at 250 uM added together with virus and measured at 10 hrs post infection by RT-qPCR method, NULL = NULL μM.	29906392
Klicka för att visa mer experimentella data för cellinjer

Kemisk information, lagring & stabilitet (Chemical Information, Storage & Stability)

Molekylvikt	157.1	Formel	C₅H₄FN₃O₂	Lagring (från mottagningsdatumet)	3 år-20°Cpulver
CAS-nr	259793-96-9	Ladda ner SDF		Lagring av stamlösningar	1 år-80°Ci lösningsmedel 1 månad-20°Ci lösningsmedel
Synonymer	N/A			Smiles	C1=C(N=C(C(=O)N1)C(=O)N)F

Löslighet (Solubility)

In vitro
Batch:

DMSO : 31 mg/mL (197.32 mM)
(Fuktkontaminerad DMSO kan minska lösligheten. Använd färk, vattenfri DMSO.)

Water : 2 mg/mL

Ethanol : 2 mg/mL

Molaritetsräknare

Massa	Koncentration	Volym	Molekylvikt
=	×	×

Utspädningsräknare Molekylviktsräknare

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validerad av Selleck-laboratorier. Om du behöver justeringar av denna formulering, kontakta vårt säljteam för skräddarsydd testning.	1.550mg/ml (9.87mM)	Taking the 1 mL working solution as an example, add 50 μL of 31 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validerad av Selleck-laboratorier. Om du behöver justeringar av denna formulering, kontakta vårt säljteam för skräddarsydd testning.	1.550mg/ml (9.87mM)	Taking the 1 mL working solution as an example, add 50 μL of 31 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo-formuleringsräknare (Klar lösning)

Steg 1: Ange information nedan (Rekommenderas: Ett extra djur för att ta hänsyn till förluster under experimentet)

Dosering: mg/kg Djurens medelvikt: g Doseringsvolym per djur:μL Antal djur:

Steg 2: Ange in vivo-formuleringen (Detta är endast räknaren, inte formuleringen. Vänligen kontakta oss först om det inte finns någon in vivo-formulering i löslighetsavsnittet.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Beräkningsresultat:

Arbetskoncentration: mg/ml;

Metod för att bereda DMSO-stamlösning: mg substans förlöst i μL DMSO ( Stamlösningskoncentration mg/mL, Vänligen kontakta oss först om koncentrationen överskrider DMSO-lösligheten för denna batch av substansen. )

Metod för att bereda in vivo-formulering: Ta μL DMSO stamlösning, tillsätt sedanμL PEG300, blanda och klarna, tillsätt sedanμL Tween 80, blanda och klarna, tillsätt sedan μL ddH₂O, blanda och klarna.

Metod för att bereda in vivo-formulering: Ta μL DMSO stamlösning, tillsätt sedan μL Majsolja, blanda och klarna.

Obs: 1. Se till att vätskan är klar innan du tillsätter nästa lösningsmedel.
2. Se till att tillsätta lösningsmedlet/lösningsmedlen i ordning. Du måste se till att lösningen som erhålls i föregående tillsats är en klar lösning innan du fortsätter att tillsätta nästa lösningsmedel. Fysiska metoder som vortex, ultraljud eller varmt vattenbad kan användas för att underlätta upplösningen.

Verkningsmekanism (Mechanism of Action)

Targets/IC₅₀/Ki	RNA-dependent RNA polymerase
In vitro	Favipiravir (T-705) shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), it shows no cytotoxicity at concentrations up to 1,000 μg/ml. In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, this compound induces lethal mutagenesis.
In vivo	Favipiravir (T-705) protects influenza virus-infected mice from death when administered at 200 mg/kg/day (p.o.). In mice experimentally infected with Ebola virus, this compound efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6 days after initiation of treatment, respectively.
Referenser	[1] https://pubmed.ncbi.nlm.nih.gov/11897578/ [2] https://pubmed.ncbi.nlm.nih.gov/23325689/ [3] https://pubmed.ncbi.nlm.nih.gov/26343011/

Applikationer (Applications)

Metoder	Biomarkörer	PMID
Growth inhibition assay	Survival Cell viability	26711718
IHC	H&E Staining NiV nucleoprotein LASV antigen H&E stain	29765101
Immunofluorescence	rNiV-Gluc	29765101

Klinisk prövningsinformation (Clinical Trial Information)

(data från https://clinicaltrials.gov, uppdaterad den 2026-08-07)

NCT-nummer	Rekrytering	Tillstånd	Sponsor/Samarbetspartners	Startdatum	Faser
NCT06860334	RECRUITING	Crimean-Congo Hemorrhagic Fever	Liverpool School of Tropical Medicine	2026-06-04	PHASE2
NCT06024421	RECRUITING	Infectious Disease; Pharmacology	Institut National de la Santé Et de la Recherche Médicale, France	2024-05-14	PHASE1
NCT06212336	RECRUITING	Lassa Fever	Irrua Specialist Teaching Hospital	2025-05-02	PHASE2; PHASE3
NCT04746183	RECRUITING	Covid19	University of Liverpool	2020-07-03	PHASE1; PHASE2
NCT05648448	RECRUITING	Influenza; Influenza, Human	University of Oxford	2023-02-22	PHASE2
NCT06488300	RECRUITING	Respiratory Syncytial Virus; Respiratory Syncytial Virus, Human	University of Oxford	2024-07-25	PHASE2

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):